Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-007056
Filing Date
2024-05-07
Accepted
2024-05-07 16:16:02
Documents
90
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ymab-20240331x10q.htm   iXBRL 10-Q 2023523
2 EX-10.3 ymab-20240331xex10d3.htm EX-10.3 40136
3 EX-10.4 ymab-20240331xex10d4.htm EX-10.4 29683
4 EX-31.1 ymab-20240331xex31d1.htm EX-31.1 15593
5 EX-31.2 ymab-20240331xex31d2.htm EX-31.2 15555
6 EX-32.1 ymab-20240331xex32d1.htm EX-32.1 7773
7 EX-32.2 ymab-20240331xex32d2.htm EX-32.2 7732
8 GRAPHIC ymab-20240331xex10d3001.jpg GRAPHIC 3403
  Complete submission text file 0001558370-24-007056.txt   8562166

Data Files

Seq Description Document Type Size
9 EX-101.SCH ymab-20240331.xsd EX-101.SCH 62884
10 EX-101.CAL ymab-20240331_cal.xml EX-101.CAL 44959
11 EX-101.DEF ymab-20240331_def.xml EX-101.DEF 276519
12 EX-101.LAB ymab-20240331_lab.xml EX-101.LAB 499612
13 EX-101.PRE ymab-20240331_pre.xml EX-101.PRE 440090
94 EXTRACTED XBRL INSTANCE DOCUMENT ymab-20240331x10q_htm.xml XML 1394197
Mailing Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169
Business Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169 212-847-9841
Y-mAbs Therapeutics, Inc. (Filer) CIK: 0001722964 (see all company filings)

EIN.: 474619612 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38650 | Film No.: 24922117
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)